Polymer coatings initially aimed at urinary tract infections

Basic Information

The company is focused on building revenues through the development and licensing of proprietary polymer coatings that resist attachment of biofilms. Biofilms are thin layers of microorganisms which aggregate on the surface of implanted medical devices and cause inflammation and infection. The unique chemical polymer resists the attachment of the organisms that create the biofilm.

The first commercial product is a coating that prevents catheter-acquired urinary tract infections (CAUTIs). CAUTIs are estimated to cost the NHS £100m each year, with 17% of hospitalized patients developing a CAUTI which must be treated at an average cost of £1,327 per case. Current products on the market show limited effectiveness and with 100 million catheters sold to hospitals worldwide each year, the market value is in excess of £375 million pa.

There are further opportunities for use in cardiac stents and other implanted medical devices, as well as derivative formulations in dental and marine products.
 

Based in Cambridgeshire, seeking investment of £250,000.

Back to Listing